Pfizer (PFE) CEO Albert Bourla Receives Award of 22 Phantom Shares

What Happened Albert Bourla, Pfizer’s Chairman & CEO and a director, was granted 22 units that represent phantom shares of common stock on 2026-09-15. The units are valued at $27.55 each for a total reported value of $606. The transaction is coded as an award/grant (A) and is a derivative award rather than an open-market purchase.

Key Details

• Transaction date and price: 2026-09-15, 22 units at $27.55 each (total $606).
• Shares/units after transaction: not disclosed in the filing.
• Footnotes: F1 — each unit represents one phantom share; F2 — units were granted under the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan and are cash-settled upon separation from service; the reporting person may transfer them into an alternative investment account at any time.
• Filing timeliness: Reported on 2026-09-16 for the 2026-09-15 transaction (filed promptly).

Context This was a compensation award of phantom (derivative) units that are settled in cash after departure from the company, not a market purchase or sale of common stock. Such awards are routine elements of executive pay and do not by themselves indicate the insider’s view on the company’s stock.